Deutsche Bank AG Invests $2.31 Million in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Deutsche Bank AG acquired 62,228 Agios Pharmaceuticals shares in the second quarter, valued at approximately $2.31 million and representing about 0.10% of the company.
• Several major institutional investors increased their Agios positions, including Wellington Management, State Street, Bellevue Group, Erste Asset Management and Commodore Capital.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $41.25 price target, despite Agios reporting a quarterly EPS loss of $1.69 that narrowly missed estimates.

Deutsche Bank AG bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 62,228 shares of the biopharmaceutical company's stock, valued at approximately $2,309,000. Deutsche Bank AG owned approximately 0.10% of Agios Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Bellevue Group AG boosted its position in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company's stock worth $149,110,000 after purchasing an additional 124,586 shares during the period. State Street Corp raised its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock valued at $84,604,000 after purchasing an additional 845,433 shares during the period. Erste Asset Management GmbH raised its position in Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company's stock valued at $76,343,000 after purchasing an additional 40,000 shares during the period. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after purchasing an additional 2,049,287 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in shares of Agios Pharmaceuticals by 6.4% during the second quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company's stock worth $77,330,000 after purchasing an additional 140,000 shares in the last quarter.

Analyst Ratings Changes

AGIO has been the subject of several analyst reports. Truist Financial decreased their target price on Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. HC Wainwright upped their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Citigroup increased their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Finally, Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $41.25.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $34.28 on Friday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -4.89 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00. The company's fifty day moving average price is $35.91 and its two-hundred day moving average price is $31.62.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current year.

Insider Buying and Selling

In related news, insider Sarah Gheuens sold 30,000 shares of the business's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares of the company's stock, valued at $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source